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Abstract

OBJECTIVES: Paediatric vitamin D (25-hydroxyvitamin D - 25OHD) deficiency can lead to
nutritional rickets and extra-skeletal complications. Compliance with daily therapy can be
difficult, making high dose, short-term vitamin D (stoss) therapy attractive to correct vitamin
D deficiency. We compared the effectiveness and safety of standard versus stoss therapy in
treating childhood 25OHD deficiency.
STUDY DESIGN: Children aged 2 - 16 years with 25OHD <50nmol/L were randomized to
either standard (5,000IU daily for 80 days) or stoss (100,000 IU weekly for 4 weeks)
cholecalciferol. Participants underwent evaluation of effectiveness and safety. 25OHD,
random spot calcium: creatinine ratio (Ca:Cr) and compliance were measured at 12 weeks.
RESULTS: 151 children were enrolled in the study (68 standard and 83 stoss), median age 9
years (IQR: 6 - 12 years). Baseline 25OHD levels were 26 nmol/L (IQR: 19 - 35 nmol/L) and
32 nmol/L (IQR: 24 - 39 nmol/L) in the standard and stoss groups respectively. At 12 weeks,
the median 25OHD level was significantly greater in the standard vs. stoss group (81 vs. 67
nmol/L; p=0.005), however, >80% of participants in both groups achieved sufficiency
(25OHD>50nmol/L) and had normal urinary Ca:Cr, with no significant difference seen
between groups. Compliance was similar in the two groups.
CONCLUSION: Compared to stoss, standard therapy achieved higher 25OHD levels at 12
weeks; however, in both groups there were a similar proportion of participants who achieved
25OHD sufficiency, with no evidence of toxicity. Unlike other studies, simplifying the
treatment regimen did not improve compliance. These results support stoss therapy as an
effective and safe alternative therapy for the treatment of paediatric vitamin D deficiency.
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Abbreviations

25OHD: 25- hydroxyvitamin D
ALP: Alkaline phosphatase
BMI: Body Mass Index
Ca:Cr: Calcium to creatinine ratio (random spot test)
CHW: Children’s Hospital at Westmead
IQR: Inter-quartile range
PTH: Parathyroid hormone
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Briefpoints

1. What is already known on this topic?



Vitamin D deficiency is a significant, but treatable, problem worldwide, resulting in
disruption to bone homeostasis and clinical rickets.
There are a number of Vitamin D formulations that have been studied; however, their
safety and effectiveness is variable.

2. What this paper adds?



This paper provides evidence for the use of this high dose formulation (100,000 IU a
week for 4 weeks) as a safe and effective alternative to standard daily therapy.
Provides physicians with an alternative dosing regime, especially in situations where
patients struggle with compliance to the standard daily regime.
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Chapter One: Literature Review
Vitamin D is critical for calcium homeostasis and for mineralization of the skeleton,
especially during the growing years. Vitamin D is produced primarily by the absorption of
UV-B rays from the sun, as well as through the dietary intake. The UV-B rays are absorbed
by 7-dehydrocholesterol in the skin to form pre-vitamin D3, which is then quickly
transformed into vitamin D through isomerisation(1). Vitamin D is then carried using specific
α1-globulin to the liver, where it undergoes conversion to 25-hydroxyvitamin D (calcidiol),
which has minimal biological activity. The newly formed calcidiol can go one of two ways. It
can either be inactivated and excreted or it can be carried to the kidneys by vitamin D–
binding protein, where it undergoes further hydroxylation to form 1,25(OH)2D3 (calcitriol),
the major biologically active metabolite(2). Through this pathway, the calcitriol metabolite
will be involved in the metabolism of calcium and phosphate, by acting on the intestine to
increase the absorption of calcium and phosphate, as well as providing negative feedback to
the parathyroid gland and kidneys (2).

In Australia, the majority of infants and children have adequate skin exposure to sunlight for
vitamin D synthesis(3). The factors that impact the vitamin D levels, produced by sunlight
exposure, include the location and timing of skin exposure, skin colour, age, clothing,
sunscreen use and disability(4). The recommended amount of sunlight exposure is 1/3
minimal erythema dose, or MED, which is the minimum amount of sun exposure to produce
slight reddening of the skin. However, excessive sun exposure will result in breakdown of
pre-vitamin D3 and vitamin D3 into inactive photoproducts(5).
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In countries where it is not possible to depend on adequate skin exposure to sunlight for
vitamin D synthesis, e.g. Canada, liquid dairy products are fortified with vitamin D and
vitamin D supplementation is recommended for all infants and children.

Vitamin D deficiency results in decreased small bowel calcium absorption and thus serum
calcium. This in turn leads to a compensatory increase in parathyroid hormone and alkaline
phosphatase, and urinary phosphate loss(5). This is costly for the paediatric patient leading to
rickets (a mineralization defect at the growth plates) and osteomalacia (a mineralization
defect of bone tissue). These effects are associated with pain, fractures, skeletal deformity,
growth retardation, dental enamel defects, delayed developmental milestones and, in severe
cases, hypocalcaemic tetany and seizures(6). If not recognized and properly treated, simple
vitamin D deficiency may have long-term sequelae. On the other hand, the disease is entirely
preventable with simple dietary measures or vitamin supplementation and readily treated with
vitamin D.

Epidemiology of vitamin D deficiency in Australia
Despite the apparent adequacy of sunlight and thus UVB exposure in Australia, and the
public health measures introduced in other countries, evidence suggests that simple vitamin D
deficiency is increasing in Australia, especially in the immigrant population(7) and in
developed countries worldwide(8, 9). Simple vitamin D deficiency is more common in babies
born to vitamin D deficient mothers (particularly if exclusively breast fed), children with dark
skin, children who cover their skin for cultural reasons and children who get limited exposure
to sunlight most commonly in association with chronic disease(7). Within The Sydney
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Children’s Hospital Network (Westmead Campus) (SCHN (Westmead Campus)), the two
major clinics where children with simple vitamin D deficiency are seen are the Health
Assessment for Refugee Kids clinic (HARK) and the Endocrine clinic. HARK commenced at
SCHN (Westmead Campus) in May 2005, sees patients on a weekly basis and currently
screens for vitamin D deficiency. Approximately 20-25% (n=44) of total refugees seen at
HARK clinic in 2005 and 2006, have had vitamin D levels <31 nmol/L, indicating vitamin D
deficiency. The endocrine clinic sees approximately one family per week with vitamin D
deficiency.
The precise incidence of simple vitamin D deficiency rickets in Australia is unknown;
however, in 2006, the incidence of nutritional rickets in Australia was estimated at
4.9/100,000/year, with the majority of cases found in immigrants and refugee populations
(10).

Management of Simple Vitamin D Deficiency
A recent consensus statement outlined the current knowledge on the prevention and treatment
of simple vitamin D deficiency during infancy and childhood(7). The premise of treating
children with simple vitamin D deficiency is to replenish the body stores of vitamin D with
either ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) so as to normalise serum
25- hydroxyvitamin D and alkaline phosphatase concentrations. This requires a total vitamin
D dose of between 400,000 and 500,000 IU. The most widely accepted and researched
method for this is with a daily dose of 1000 IU for 80 to 90 days(11). It is our experience that
adherence to this regimen can be difficult, which results in treatment failure.
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Stoss therapy, the provision of the total vitamin D treatment dose (400,000 – 500,000 IU) in 1
to 4 doses, has the potential to improve adherence and thus cure rates. Although used widely
in developing countries (12), it is not in routine use in Australia and there are limited data on
its efficacy and safety(7).

Summary
This study will compare the safety and efficacy of stoss therapy (100,000 IU cholecalciferol
weekly for 4 weeks) with standard therapy (5000 IU ergocalciferol daily for 80 days). This
study has the potential to change and improve the clinical management of simple vitamin D
deficiency in children in Australia by shortening and simplifying the treatment regimen,
which may improve adherence and cure rates.
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Chapter Two: Manuscript

Introduction

Vitamin D is crucial for calcium homeostasis and skeletal health throughout the lifespan. It is
especially important to recognize and treat 25OHD deficiency in children to prevent
osteomalacia and nutritional rickets, which can lead to pain, short stature, skeletal deformities
and extra-skeletal complications including hypocalcemic seizure, cardiomyopathy and rarely
death(7). 25OHD deficiency results in decreased calcium and phosphorous absorption across
the gastrointestinal tract, resulting in calcium deprivation and hypocalcaemia. In response,
parathyroid hormone (PTH) is released to stimulate the reabsorption of calcium and excretion
of phosphorous via the kidneys. While this may normalize serum calcium levels, it reduces
bone mineralization and results in osteomalacia and rickets(13). In addition, the presence of
the vitamin D receptor in lymphocytes, beta islet cells and major organs suggests that 25OHD
and its metabolites may have important clinical effects outside mineral homeostasis (14). It
has been suggested that 25OHD deficiency is associated with various disease processes such
as exacerbation of asthma and bronchiolitis (15, 16)
In Australia, the majority of children have adequate exposure to UVB to maintain sufficient
serum levels of vitamin D (25OHD >50nmol/L) (3). In 2006, the incidence of nutritional
rickets in Australia was estimated at 4.9/100,000/year, with the majority of cases found in
immigrants and refugee populations (10). With the recent 2015-2017 global refugee crisis,
this is likely to increase (17). Multiple factors can contribute to 25OHD deficiency in
children including lack of sun exposure, dark skin colour/ increased skin pigmentation, and
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malabsorption. Breastfed infants born to 25OHD deficient mothers are particularly at risk
(18).
A global consensus statement on the treatment of nutritional rickets, recommended a daily
vitamin D dose, in children greater than 2 years of age, of 3,000-6,000IU per day with
calcium supplementation to correct 25OHD deficiency and treat rickets (19). The American
Academy of Paediatrics suggests treating 25OHD deficiency in children >12 months with
vitamin D therapy of 5,000 IU per day for 2-3 months (11, 13). These recommended doses
would be equivalent to a combined total vitamin D dose of between 300,000 and 450,000 IU.
Adherence to a daily dosing regimen can be difficult in some patients, in which case a stoss
(from the German word stossen ‘to push’) therapy has been recommended (20, 21). Although
Stoss therapy is widely used in developing countries (12), it is not routinely used in Australia.
There are limited data on its efficacy, safety and effective dosing regimen (20-22).

This study aimed to compare the safety and efficacy of stoss therapy (100,000 IU
cholecalciferol weekly for 4 weeks) versus standard therapy (5,000 IU cholecalciferol daily
for 80 days).

Methods
Design/Participants
Children between the ages of 2 and 16 years with 25OHD status < 50 nmol/L who were
referred to the Endocrinology and/or the Refugee clinic at the Children’s Hospital at
Westmead (CHW), Sydney, Australia from 2011 to 2016 were recruited into a randomized
controlled trial of standard dose vs. high dose of cholecalciferol (vitamin D3)
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supplementation. Children were excluded if they presented one or more of the following: (1)
A pre-existing medical condition predisposing to 25OHD deficiency (e.g. malabsorption,
liver failure); (2) Current use of any medications known to alter bone metabolism (e.g.
bisphosphonates, cholecalciferol, calcitriol, anticonvulsants, barbiturates); or (3) An
underlying metabolic or genetic aetiology for rickets (e.g. X-linked hypophosphatemic
rickets). All participants were under the care of a paediatric endocrinologist or paediatrician
at CHW. Parents or legal guardians of the participants provided informed consent and the
study was approved by the Sydney Children’s Hospitals Network Human Research Ethics
and Governance Committees (#12SCHN401).

Intervention
Using random number tables, participants were randomized by family to receive either
standard therapy with cholecalciferol 5000 IU (5000 IU/mL) daily for 80 days or stoss
therapy, cholecalciferol 100,000 IU (50,000 IU/mL) weekly for 4 weeks. Both treatments
were provided by BioCeuticals. Each batch was assessed by the Quality Team before being
released, to ensure adequate but not excessive amounts of cholecalciferol in the products (23).
Recognizing the relationship between low dietary calcium intake and vitamin D status in the
pathogenesis of osteomalacia and nutritional rickets (17), both groups were also
supplemented with 500mg elemental calcium for 4 weeks. Pharmacy study investigators
reviewed appropriate administration of the medications with participants or caregivers prior
to commencing therapy. All other study investigators were blinded to the treatment
allocation.
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Data Collection
A questionnaire previously used to collect data for nutritional rickets study (10) was used to
collect baseline demographic and nutritional data and risk factors for the development of
25OHD deficiency (Appendix A ). All participants underwent a medical visit at baseline, 4
weeks, and 12 weeks. Height was measured using a Harpenden Stadiometer (Holtain Ltd,
UK) and weight was measured using the same electronic scale. Participants were questioned
to assess for any adverse events such as polyuria, polydipsia, abdominal pain and
constipation.

Primary endpoints
Primary endpoints were normalisation of 25OHD and serum alkaline phosphatase (ALP)
status at 12 weeks.

Secondary endpoints
Secondary endpoints included raised urinary Ca:Cr ratio, PTH, or elevated serum calcium
levels

Compliance Monitoring
Compliance was assessed by counting the number of empty vials returned at week 12 in the
1st group (standard therapy) and week 4 in the 2nd group (Stoss therapy). A patient was noted
to be compliant when having returned at least 75% of the vials empty.

Laboratory Measurements and Quality Assurance
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Serum and urine biochemistry data were collected at baseline, 4 weeks, and 12 weeks. Serum
biochemistry, including calcium, magnesium, phosphate and alkaline phosphatase (ALP),
were measured using Vitros 5600 analyser, colorimetric (Ortho Clinical Diagnostics, USA).
Parathyroid hormone (PTH) was measured using Immulite Autoanalyser,
Chemiluminescence (Siemens Healthcare, UK). Serum 25OHD was measured using Xevo
TQ-S (Tandem Quadrapole series) liquid chromatography tandem mass spectrometry (LCMS/MS) (Waters Pty Ltd, UK) as of July 2015 or IDS iSYS Autoanalyser,
Chemiluminescence (Immunodiagnostic Systems Holdings PLC, UK) from 2010 – June
2015. The results between the two methods were comparable (Figure 1). The internal control
for the TQS LC-MS/MS is is from ClinChek. The lower control is 25-OH-vitamin D 3
37.1mmol/L and 25-OH-Vitamin D 2 35.5mmol/L. The upper control value is 25-OHvitamin D 3 105mmol/L and 25-OH-Vitamin D 2 103mmol/L.

IDS-iSYS vs LC-MS for 25OHD measurement
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Fig. 1: Comparison of the two assays (iSYS and LC-MS/MS) used in this study for 25OHD
measurement using 59 DEQAS samples.

Biochemistry clinical ranges and cut-off values are consistent with paediatric norms (24).
Vitamin D status was defined in accordance with the Australian and New Zealand Consensus
Statement:(7)


Sufficiency: ≥ 50nmol/L



Deficiency: < 50nmol/L

There continues to be discussion surrounding the definition of vitamin D deficiency. The
protocol for this study was written and implemented prior to the global consensus
guidelines(17). This study uses a higher threshold for vitamin D deficiency, which is
consistent with other published guidelines (5, 7, 16, 17, 19).
Statistical Methods
Power calculations estimated a total of 111 participants needed to detect a 10% difference in
treatment success between the 2 groups, with 80% power and 5% level of significance.
Group differences in primary and secondary endpoints were determined using student t-test
for continuous variables and Chi-squared test for categorical data. Statistical calculations for
group differences with small outcomes were determined using the Fisher Exact test. All
statistical analyses were based on intention to treat principle and performed using SAS
version 9.3 and R version 3.2.4.

Results
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A total of 170 participants were randomly assigned to the stoss (n = 93) or standard therapy
group (n=78; Figure 2). Randomisation occurred by family; therefore, there was a notable
difference in sample size between the two groups. Sixteen children were excluded from the
study due to 25OHD levels ≥ 50 nmol/L at baseline. A further two participants were excluded
because they did not have any recorded 25OHD levels at baseline and one child who was
over the age of 16 years. The final number of participants who received treatment was 151,
with 68 and 83 in the standard and stoss group, respectively. There were 16 lost to follow up,
with absent 25OHD levels at 12 weeks. The final analysis was made up of a total of 135
participants, with 62 and 73 participants in the standard and stoss group, respectively.

Participants Recruited and
Consented (n= 170)

Excluded from the analysis (n=19)
- Baseline 25OHD
≥50nmol/L (n=16)
- 25OHD Baseline data
missing (n=2)
- Age > 16 years (n=1)
Participants randomized
(n=151)

Standard (n= 68)
Lost to follow
up (n=6)
- no 25OHD
levels at 12
weeks

Stoss (n= 83)

Lost to follow up
(n=10)
- no 25OHD levels at
12 weeks
18

Standard (n= 62)

Stoss (n= 73)

Fig. 2: Consort* Flow Diagram of participants throughout this study. *Consolidated
Standards of Reporting Trials

Patient characteristics were similar in both groups. The age of the participants ranged from 2
to 16 years with a median of 9 years (Table 1). The majority of the participants were of
Middle Eastern and African descent, with the Middle Eastern ethnicity over represented in
the stoss group (Table 1). Height, weight and BMI data were similar across both groups
(Table 1).

Table 1: Baseline characteristics of all participants in the final analysis
Characteristic

Standard (N=68)

STOSS (N=83)

All (N=151)

Female, n (%)

32 (47)

39 (47)

71 (47)

Age (years)
median (IQR)

9 (6 -12)

8 (5-11)

9 (5 -12)

16 (24)

15 (18)

31 (21)

9 (13)

8 (10)

17 (11)

5 (7)

6 (7)

11 (7)

Indian subcontinent, n (%)

16 (24)

12 (14)

28 (19)

Middle Eastern, n (%)

16 (24)

35 (42)

51 (34)

6 (9)

7 (8)

13 (9)

Ethnicity
African, n (%)
Asian, n (%)
Caucasian, n (%)

Other, n (%)
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Characteristic
Weight (kg)*
median (IQR)
Weight z-score+ median
(IQR)
Height (cm)*
median (IQR)
Height z-score+ median
(IQR)

Standard (N=68)

STOSS (N=83)

All (N=151)

34 (19 - 51)

30 (20 - 39)

30 (19 - 44)

0.4 (-0.6 - 1.0)

0.1 (-0.8 - 0.6)

0.2 (-0.8 - 0.8)

136 (115 - 157)

134 (110 - 146)

134 (114, - 151)

0.0 (-0.7 - 1.0)

-0.3 (-1.2 - 0.8)

-0.2 (-1.1 - 0.9);

BMI# z-score+ median
0.1 (-0.9 - 0.9)
0.2 (-0.6 - 0.9)
0.1 (-0.8 - 0.9)
(IQR)
*Data available for 61 participants in standard group, 72 participants in stoss group with a
total of 133 participants.
+
Centre for Disease Control 2000 Growth Charts
#
Body Mass Index (BMI)
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The median 25OHD level at baseline was significantly lower in the standard group, compared
to the stoss group (26 vs. 32nmol/L; p=0.01). The median 25OHD status for both groups
increased to sufficient status (≥ 50nmol/L) at 4 and 12 weeks (Figure 3; Table 2). However,
the median 25OHD level at 12 weeks was significantly greater in the standard group (81 vs.
67 nmol/L; p=0.005) (Figure 3; Table 2).

Fig. 3: Comparison of 25OHD levels throughout the study. One extreme outlier in the
standard therapy group with a 25OHD level of 440nmol/L at 4 weeks was not included in
this box plot. (*p<0.05).
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Table 2: Median levels of 25OHD, PTH and ALP at baseline, 4 weeks and 12 weeks
Standard (N=68)
STOSS (N=83)
p-value§
25OHD (nmol/L): Median# (IQR); n
Baseline

26 (19 - 35); n=68

32 (24 -39); n=83

0.01

Week 4

104 (65 -142); n=53

113 (90 -153); n=78

0.10

Week 12

81 (59 -124); n=62

67 (55 -78); n=73

0.005

PTH (nmol/L): Median (IQR); n
Baseline

4.3 (2.7 -6.2); n=66

4.2 (3.0 -6.8); n=76

0.69

Week 4

2.5 (1.6 -4.0); n=53

2.8 (1.7 -3.7); n=77

0.81

Week 12

2.6 (1.7 -4.6); n=62

3.8 (2.3 -5.4); n=74

0.01

ALP (nmol/L): Median (IQR); n
Baseline

218 (184 -307); n=67

221 (155 -281); n=77

0.39

Week 4

220 (176 -282); n=53

224 (170 -273); n=76

0.98

Week 12
224 (176 -284); n=63
224 (184 -288); n=72
§
Calculated using Mann-Whitney-Wilcoxon Test
#
Median levels used because the data had a non-normal distribution

0.68

Change in 25OHD levels between baseline and 12 weeks was greater in standard (50 nmol/L
change; IQR 35 - 98 nmol/L) vs. stoss group (35 nmol/L change; IQR 25 - 36 nmol/L;
p=0.0005). At both 4 and 12 weeks, the proportion of participants who were vitamin D
sufficient did not differ between the groups (Table 3). At 4 weeks, there were two children in
the standard and one in the stoss group with 25OD levels within the elevated range
(>250nmol/L). At 12 weeks, there were two participants in the standard group, and no
participants in the stoss group, with elevated levels of 25OHD. None of those with elevated
25OHD status had raised urinary Ca:Cr ratio or elevated serum calcium levels. As both
elevated 25OHD levels and hypercalciuria are required for a diagnosis of vitamin D toxicity
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(1), none of the participants met these criteria. Therefore, the treatment regimen was
continued and further 25OHD measurements were found to be below 250nmol/L.

Table 3: Proportion of participants with biochemical levels within normal range
Standard

Stoss

OR (STOSS vs. Standard)
(95% CI)

p-value

25OHD below normal limits (<50 nmol/L)
Week 4

5/53 (9%)

3/78 (4%)

0.39 (0.05 – 2.09)

0.27*

Week 12

12/62 (19%)

11/73 (15%)

0.74 (0.27, 2.00)

0.67*

25OHD within normal limits (50-250 nmol/L)
Week 4

46/53 (87%)

74/78 (95%)

2.60 (0.59 - 11.40)

0.19

Week 12

49/62 (79%)

62/73 (85%)

1.35 (0.55 - 3.32)

0.51

25OHD greater than normal limits (> 250 nmol/L)
Week 4

2/ 53 (4%)

1/78 (1%)

0.33 (0.01, 0.57)

0.56*

Week 12

1/62 (2%)

0/73 (0%)

0 (0.00, 33.12)

0.46*

PTH within normal limits (1-7 pmol/L)
Week 4

47/53 (89%)

68/77 (88%)

0.96 (0.32 - 2.89)

0.95

Week 12

55/62 (89%)

63/74 (85%)

0.73 (0.26 - 2.01)

0.54

1.22 (0.35 - 4.21)

0.76

ALP within normal limits (50-320 U/L)
Week 4

48/53 (91%)

70/76 (92%)

Week 12
56/63 (89%)
67/72 (93%)
1.68 (0.50 - 5.57)
0.40
OR and p-values calculated using Chi square test unless otherwise indicated
* Calculated using the Fisher exact test. (instead of the chi square test used in the remainder
of the analysis as it is more precise when assessing small samples).

Median PTH and ALP levels were within normal limits throughout the study (Figures 4 and
5; Table 2). Both markers had similar median levels between the two groups at baseline and
4 weeks; however, the median PTH level at 12 weeks was significantly higher in the stoss
group (3.8 vs. 2.6 pmol/L; p=0.0115)(Figures 4 and 5; Table 2). The majority of participants
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had PTH levels measured within normal range, at 4 and 12 weeks, with no significant
difference between the two groups (Table 3).

Fig. 4: Comparison of PTH levels throughout the study. One extreme outlier in the
standard group with a PTH level of 102pmol/L at baseline was not included in this box plot

Fig. 5: Comparison of ALP levels throughout the study. One extreme outlier in the stoss
group with an ALP level of 1190U/L at baseline was not included in this box plot
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There were no cases of hypo or hypercalcemia in the cohort. In both groups, urinary Ca:Cr
ratios were similar throughout the length of follow-up (0.11-0.25; p>0.3). Over 80% of
participants had normal urinary Ca:Cr ratio. Those with an elevated ratio had normal serum
25OHD levels.

Compliance data was unavailable for half of the cohort. From the data available, there was no
significant difference in compliance between the stoss and standard groups (Table 4).

Table 4: Compliance with Vitamin D therapy
OR
Characteristic
Standard
STOSS
(95% CI)
Compliance with
1.29
23/30 (77%) 38/47 (81%)
Vitamin D therapy*
(0.42 - 3.92)
* A participant was compliant when ≥75% of vials were returned empty.

P-value
0.66

Discussion
We aimed to compare the safety and efficacy profiles of standard and stoss vitamin D therapy
in a cohort of children with suboptimal 25OHD levels (25OHD <50nmol/L) (17). Both
treatment regimens were found to be similar in safety and effectiveness in normalising
25OHD levels in children, despite a small percentage of children who had 25OHD levels
above the normal range. However, the overall 25OHD level was higher in the standard group
at 12 weeks and the toxicity beyond a 12-week course has not been investigated in this study.

25

There are various studies identifying baseline characteristics, such as 25OHD level, ethnicity,
age, BMI and sex as predictors of treatment response (25-28). In our study, baseline
characteristics (i.e. ethnicity, sex and anthropometry) were similar between the two groups
indicating that appropriate randomization was achieved and in so doing accounted for these
characteristics as confounding factors. In the overall cohort the disproportionate
representation of 25OHD levels <50nmol/L amongst immigrant and ethnic populations, is
consistent with findings in other studies (7, 29-31). Despite randomization, the baseline
median 25OHD level was statistically lower in the standard group compared to the stoss
group (Table 2). This does not explain the 14nmol/L greater 25OHD value in the standard
therapy group at 12 weeks (81 nmol/L v 67 nmol/L). With both groups having similar levels
of sufficiency, it is not possible to say that this difference in 25OHD level would have
clinical sequelae. We did not have children with nutritional rickets in the study and are unable
to comment on the efficacy of either therapy in its treatment. The median 25OHD level in the
standard group was statistically higher than the stoss group at 12 weeks. While it was not
associated with significant differences in ALP, serum calcium or urinary Ca:Cr it was
associated with a relative reduction in PTH levels, indicating that it did have an effect on
calcium homeostasis.

Multiple studies, with varying treatment regimens, support stoss therapy as an effective way
to normalize 25OHD status (7, 32, 33). A study of 42 children with vitamin D deficiency
(25OHD <50nmol/L) found that a total single dose of 150,000 IU significantly increased
25OHD levels compared to 84,000IU given as 2,000IU/day for 6 weeks (125nmol/L and
60nmol/L respectively) (electrochemiluminescense enzyme immunoassay method) (33).
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Compared to the above study, where the stoss dose was almost twice that of the daily total
dose, our study gave the same total vitamin D dose in the stoss and standard treatment arms
and did not see such large difference between treatment groups. A small prospective cohort
study of 18 children with cystic fibrosis showed replenishment of 25OHD levels in 17, using
a total ergocalciferol dose of 700,000IU (50,000IU daily for 2 weeks) (28). However, it is
important to note that 25OHD 75nmol/L was used as the cut-off for sufficiency and the
participants included those with pancreatic insufficiency and suboptimal vitamin D
absorption. Shepherd et al 2015, found a significant increase in mean 25OHD levels amongst
children with inflammatory bowel disease one month post treatment with stoss therapy
ranging from 200,000-800,000 IU given as a single dose (The 25OHD assayed using
automated Liason system (DiaSorin Corp, Saluggia, Italy) (32). A single high stoss dose of
600,000IU of cholecalciferol, both via oral and intramuscular administration, has been shown
to be both safe and effective in treating children (5 months to 9 years) with vitamin D
deficient rickets (20, 34).

Biochemical effectiveness of treatment of vitamin D deficiency may be assessed by
normalization in parathyroid hormone (PTH) and alkaline phosphatase (ALP) levels, markers
of total body calcium sufficiency. Reductions in both PTH and ALP have been associated
with high dose vitamin D therapy (35). The study by Emel et al (2012) found that PTH and
ALP levels were similar in both low dose vitamin D (2,000IU/day for 6 weeks) and stoss
therapy (150,000 IU once) (33). In our study ALP levels were similar in both treatment
groups, but PTH levels were lower in the standard group. This is likely a reflection of the
higher 25OHD level seen in the standard treatment group and resultant effect on mineral
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homeostasis. It should be noted however that PTH levels were normal at 12 weeks in both
treatment groups and that the difference PTH levels was not associated with any clinical
difference between groups. Whether this potential biochemical sign of increased effectiveness
of standard verses stoss therapy could be extrapolated to suggest greater effectiveness in
treatment of nutritional rickets is uncertain.

Vitamin D toxicity can be defined by 25OHD levels >250nmol/L with or without
hypercalciuria and/or hypercalcemia (17, 36). We however support a definition that is not
based solely on 25OHD levels but also on serum calcium and urinary Ca:Cr elevation(17). In
this current study, two children in the standard therapy group and one child in the stoss group
had 25OHD levels >250nmol/L. None of these children had elevated serum calcium or
urinary Ca:Cr. Our results are consistent with others in the literature. Hypercalciuria
complications have not been reported in studies using lower single doses (150,000 IU) (33,
37). Contrarily, hypercalciuria has been described in children receiving single doses of stoss
therapy 300,000 IU (38, 39).

Daily vitamin D replacement and subsequent maintenance therapy may be associated with
poor compliance, and intermittent high dose vitamin D supplementation may improve this (7,
40). In this randomized control trial, it was hypothesized that stoss therapy would result in
improved compliance; however, the compliance rates between the two groups were similar.
The external validity of our compliance data is limited by the controlled setting of the study.
Participants were aware they were required to return the packaging and remaining tablets at
the end of their treatment. This may have encouraged compliance rates greater than would
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be seen in the regular clinical setting. However, similar compliance allowed a more accurate
comparison of effectiveness and safety. It must be noted that there were missing data for
returned vitamin D medications, which may have led to an inaccurate expression of
compliance. However, the proportion of missing data was similar for both groups with no
statistical significance (p= 0.23)

Potential errors with 25OHD measurement may have been introduced because the 25OHD
assay was changed during the study period. However, we believe the impact of this change to
be minimal as results from the 2 assays were almost collinear (R2= 0.96) (see figure 1).

There are a number of strengths of this study. It is a relatively large randomized and
prospective study with a small loss to follow-up. Both groups met the required number for
the power calculation, therefore reducing type 2 errors. The children were followed to 12
weeks, providing time to investigate the study objectives. Specifically, we measured the
normalization of 25OHD levels and both serum and urine calcium levels to assess for
toxicity. The number of returned empty vials, instead of directly observing the children
taking the medication, assessed compliance. This increased external validity as it simulated a
normal clinical environment.

The majority of children in our study were from non-Caucasian ethnic backgrounds. This
represents the Australian experience of vitamin D deficiency being greater in children who
are immigrants or born to immigrant parents, compared to the overall Australian paediatric
population (7).
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Conclusion
A regimen of cholecalciferol 100,000 IU weekly for 4 weeks is a safe and effective
alternative treatment for achieving 25OHD levels in the sufficient range in children over 2
years of age. This study will provide clinicians with increased confidence in managing
vitamin D deficiency in kids, especially where compliance with a standard dosing regime
may be an issue. This study is the largest randomized control trial to date, comparing stoss
vitamin D therapy to standard therapy, in the management of vitamin D insufficiency and
deficiency in children.
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APPENDIX I
SIMPLE VITAMIN D DEFICIENCY RICKETS Questionnaire
Australian Paediatric Surveillance Unit
Please keep a record of the child's unit number in your APSU folder.
Please contact Dr Craig Munns on (02) 9845-3200 or craigm2@chw.edu.au if you have any questions about this form

REPORTING CLINICIANS DETAILS
1. APSU Dr Code
PATIENT DETAILS
2. First 2 letters of first name:
3. Date of Birth:
/
/
5. Date of diagnosis:
/
/
7. Country of birth of child:
8.
If yes, from what country?

3. First 2 letters of surname:
4. Sex:
M F
6. Postcode of family:
No Unknown
If yes, when (month/year)? /

If this patient is primarily cared for by another physician who you believe will report
the case and could provide additional data
the space below then complete
questionnaire details above this line and return to APSU. If no other report
is received for this child we will contact you for further information.
FAMILY DETAILS
Mother’s Ethnicity:
Aboriginal/Torres Strait Islander
Caucasian
Islander
Asian Middle
Eastern
Africa Latin American
9. Indian subcontinent
Other Please Specify:
10. Country of birth of mother:
Father’s Ethnicity
Aboriginal/ Torres Strait Islander
Caucasian
Islander Asian
Middle Eastern
Africa Latin American
Indian
subcontinent
Other
Please Specify:
11. Country of birth of father:
12. Number of children in the family:
1 2 3 4 5
>5
13. Number of other children in family diagnosed with simple vitamin D deficiency rickets: 1
MEDICAL HISTORY
14. Does the child have other medical conditions (including allergies to food and medications)?
Yes,
No,
DK
If yes, please specify:
15. Was the child on medications at diagnosis (other than Vitamin D)? Yes No
DK
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2

3

If yes, please specify:
16. Gestational age:
weeks DK
17. Birth-weight:
grams DK
NUTRITIONAL HISTORY CHILD
18. For children < 3 years old, how many weeks/months was the child exclusively breast fed?
weeks/months DK
19. For children < 3 years old, at what age did the child receive commercially available formula?
weeks/months DK
20. Did the child receive multi-vitamin or vitamin D supplementation prior to the diagnosis of
rickets? Yes
No
DK
If yes, which vitamin preparation was used?
DK
If yes, at what age was was the vitamin supplementation started?
weeks/months DK
If yes, for how long did the child take the vitamin supplement?
weeks/months
DK

NUTRITIONAL HISTORY MOTHER
21. Did the mother receive multi-vitamin or vitamin D supplementation
during her pregnancy? Yes
No
DK If yes, which vitamin
preparation was used?
DK If yes, what was the
If yes, for how long did the mother take the multivitamin/vitamin D supplementation?
weeks/mon
ths DK
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OTHER RISK FACTORS FOR VITAMIN D DEFICIENCY
22.
Intermediate Fair
23.
Intermediate Fair
24. Was the mother veiled during the pregnancy? Yes No DK
If yes, please tick the appropriate category below (tick one only):
, including arms, hair and neck, when
outdoors

25. Is the child veiled? Yes
No DK
If yes, please tick the appropriate category below (tick one only):
including arms, hair and neck, when
outdoors

If yes, from what age (years) has the child been veiled?

years

CLINICAL PRESENTATION AND DIAGNOSTIC STUDIES
26.
27.

(tick as many as apply): Limb deformity Fracture
Motor delay Poor growth Respiratory illness

Seizure
Hypotonia

28.(a) Was the child diagnosed during screening because of affected siblings? Yes
No
29. Were there radiological signs of rickets? Yes No
Not Done
DK
Biochemical Data at Diagnosis, If known
Parameter
Results at
Units Normal range
Diagnosis
25-Hydroxyvitamin D

DK

Alkaline phosphatase
Ionized calcium
Total calcium
Albumin
Phosphate
Parathyroid hormone
Haemoglobin
Mean corpuscular volume
(MCV)
Ferritin
TREATMENT OF RICKETS
30. Was the child commenced on treatment? Yes No
DK If yes, what was
prescribed?
Medication
Dose (units) Frequency Duration of therapy
(weeks/days/months)
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Bone p

Thank you for your help with this
research project.
Please return this questionnaire to
the APSU in the reply-paid
envelope.
The Australian Paediatric Surveillance Unit is a unit of the Royal
Australasian College of Physicians (Paediatrics and Child Health
Division) and funded by the NHMRC (Enabling Grant No. 402784 );
the Australian Government Department of Health and Ageing; and the
Faculty of Medicine University of Sydney. This study has been
approved by a Human Research Ethics Committee properly
constituted under NHMRC guidelines.
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Chapter Three: Discussion

This randomized control study has investigated the safety and effectiveness of high
dose vitamin D therapy, in the management of vitamin D deficiency, in children
between the ages of 2 and 18 years. Although there have been a number of different
dosing regimes investigated, this study has shown that this stoss therapy is similar in
efficacy and safety to standard therapy. This provides clinicians with another regime
in which to manage vitamin D deficiency based on patient preference and adherence.

This study may assist medical practitioners, including general paediatricians and
paediatric endocrinologists, in treating children with vitamin D deficiency and at risk
of poor compliance. Although this study did not show an improved compliance to
stoss therapy, this may differ in the clinical setting and in particular in areas where
there is a limited capacity for regular follow up.

There are a number of potential limitations in the reliability and reproducibility of
these results:
-

This study was undertaken in a majority of children who were of ethnic
descent; therefore, the conclusion may not be reproducible in different
clinical settings.

-

There were a small number of participants who were lost to follow up
which may have affected the final outcome.

-

The baseline 25OHD level in the standard group was significantly lower
than the stoss group, potentially reducing the median levels at 4 and 12
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weeks within the standard group. However, although the difference was
statistically significant, this was believed to be clinically insignificant.
-

Changing assays for vitamin D measurement over the study period also
may have reduced the accuracy in assessing change; however, the two
assays are closely correlated (R2= 0.96) (see figure 4).

It is important to note that this study investigated the treatment of vitamin D
deficiency, not the regular use of stoss therapy as maintenance vitamin D
supplementation. A follow up period of up to 1 year may have allowed for further
extrapolation of long term effectiveness and maintenance of 25OHD sufficiency;
however, this was not the objective of this study.

Compliance to standard vitamin D therapy may be difficult to achieve, owing to the
daily dosing over an extended period of time; thus, the potential benefit of the
simplified stoss regime. In this study, there was a significant amount of missing data
for returned vitamin D medications, with a greater amount in the standard group,
which may have led to an inaccurate expression of compliance. Compliance was also
measured by assessing the number of empty vials returned; however, this may have
underestimated the true value and could have been improved by instead measuring the
remaining volume returned.

Although there was data collected regarding the characteristics of all participants, this
was only used to establish whether or not there was effective randomization. This data
could have been further analysed to assess the influence of ethnicity, age and body
mass index on the effectiveness of 25OHD replacement. This may allow clinicians to
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further tailor the management of vitamin D deficiency in children, based on these
characteristics.
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